Autor según el artículo: Pedro Romero-Aroca; Sofia de la Riva-Fernandez; Aida Valls-Mateu; Ramon Sagarra-Alamo; Antonio Moreno-Ribas; Nuria Soler; Domenec Puig

Departamento: Enginyeria Informàtica i Matemàtiques Medicina i Cirurgia

Autor/es de la URV: ROMERO AROCA, PEDRO; Sofia de la Riva-Fernandez; VALLS MATEU, AÏDA; Ramon Sagarra-Alamo; MORENO RIBAS, ANTONIO; Nuria Soler; PUIG VALLS, DOMÈNEC SAVI

Palabras clave: Diabetic macular oedema diabetic retinopathy

Resumen: Background: Prospective, population-based study of an 8-year follow up. To determine the direct cost of diabetic retinopathy [DR], evaluating our screening programme and the cost of treating DR, focusing on diabetic macular oedema [DMO] after anti-vascular endothelial growth factor [anti-VEGF] treatment. Methods: A total of 15,396 diabetes mellitus [DM] patients were studied. We determined the cost-effectiveness of our screening programme against an annual programme by applying the Markov simulation model. We also compared the cost-effectiveness of anti-VEGF treatment to laser treatment for screened patients with DMO. Results: The cost of our 2.5-year screening programme was as follows: per patient with any-DR, €482.85 ± 35.14; per sight-threatening diabetic retinopathy [STDR] patient, €1528.26 ± 114.94; and €1826.98 ± 108.26 per DMO patient. Comparatively, an annual screening programme would result in increases as follows: 0.77 in QALY per patient with any-DR and 0.6 and 0.44 per patient with STDR or DMO, respectively, with an incremental cost-effective ratio [ICER] of €1096.88 for any-DR, €4571.2 for STDR and €7443.28 per DMO patient. Regarding diagnosis and treatment, the mean annual total cost per patient with DMO was €777.09 ± 49.45 for the laser treated group and €7153.62 ± 212.15 for the anti-VEGF group, with a QALY gain of 0.21, the yearly mean cost was €7153.62 ± 212.15 per patient, and the ICER was €30,361. Conclusions: Screening for diabetic retinopathy every 2.5 years is cost-effective, but should be adjusted to a patient's personal risk factors. Treatment with anti-VEGF for DMO has increased costs, but the cost-utility increases to 0.21 QALY per patient.

Grupo de investigación: Grup de Recerca d'Oftalmologia ITAKA: Tecnologies Intel.ligents Avançades per a la Gestió del Coneixement Robòtica i Visió Intel.ligents

Áreas temáticas: Health sciences Ciencias de la salud Ciències de la salut

Acceso a la licencia de uso: https://creativecommons.org/licenses/by/3.0/es/

ISSN: 1471-2415

Identificador del autor: N/D; N/D; N/D; N/D; N/D; N/D; N/D

Fecha de alta del registro: 2016-09-19

Volumen de revista: 16

Versión del articulo depositado: info:eu-repo/semantics/publishedVersion

Enlace a la fuente original: https://bmcophthalmol.biomedcentral.com/articles/10.1186/s12886-016-0318-x

DOI del artículo: 10.1186/s12886-016-0318-x

Entidad: Universitat Rovira i Virgili

Año de publicación de la revista: 2016

Página inicial: 136

Tipo de publicación: Article Artículo Article